Recursion Pharmaceuticals (RXRX) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 495.3% versus a loss of 18.4%. Over five years, SLS leads with a +28.1% price change compared with -77.6% for RXRX. Recursion Pharmaceuticals is the larger company by market cap ($2.29 billion vs $2.28 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RXRX | SLS |
|---|---|---|
| Share price | $4.27 | $11.31 |
| Market cap | $2.29B | $2.28B |
| 1-day change | -7.78% | -0.26% |
| YTD return | +4.40% | +200.00% |
| 1-year return | -18.36% | +495.26% |
| 5-year return | -77.57% | +28.09% |
| EPS (TTM) | $-1.00 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $15.88 |
| 52-week low | $2.77 | $1.39 |
| Distance from 52-week high | -40.53% | -28.78% |
| Analyst consensus | none | none |
| Avg. price target upside | +69.09% | +187.36% |
| Average volume | 20.24M | 6.75M |
| Shares outstanding | 535.34M | 201.95M |
| Employees | 600 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed RXRX by 513.6 percentage points over the past year.
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
RXRX vs SLS FAQ
Which is bigger, Recursion Pharmaceuticals or SELLAS Life Sciences Group?
Recursion Pharmaceuticals (RXRX) is larger, with a market capitalization of $2.29B compared with $2.28B for SELLAS Life Sciences Group (SLS).
Which stock has performed better over the past year, RXRX or SLS?
SLS returned +495.26% over the past 12 months, compared with -18.36% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Recursion Pharmaceuticals and SELLAS Life Sciences Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Recursion Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for SELLAS Life Sciences Group.